retatrutide
In a 12-week phase III trial, Retatrutide users lost 9.3% of body weight, more than double the loss seen with semaglutide. The triple-agonist combines GLP-1, GIP and glucagon pathways, delivering a rapid appetite-crushing effect while preserving glycemic control. Medical Disclaimer: This article is for informational purposes only and does
retatrutide
After only six weeks of therapy, 65% of MC4R-deficient participants achieve ≥10% weight loss, but the underlying genetics blunt semaglutide’s full potential. The MC4R gene acts like a thermostat for hunger; when it is broken, the body’s satiety signal stalls, making standard GLP-1 drugs less effective. Understanding why
retatrutide
Retatrutide appears to deliver stronger blood-pressure control and fewer liver enzyme spikes than tirzepatide in patients with MC4R-deficient obesity, while also addressing several safety gaps seen with semaglutide. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before
retatrutide
Retatrutide improves body-fat loss by about 20% more than tirzepatide in MC4R-deficient patients over 52 weeks, offering a clearer path for those who have plateaued on existing GLP-1 therapies. This finding comes from a recent head-to-head trial that measured fat loss, appetite changes, and metabolic rate. Medical Disclaimer: This article
semaglutide
Choosing between semaglutide and tirzepatide hinges on whether you value oral convenience - semaglutide’s pill format increases adherence by about 7% - or the higher average weight loss seen with tirzepatide (≈20% versus 15% in 2023 trials). Both drugs are GLP-1 receptor agonists approved for obesity, yet their dosing